Using Selection Biomarkers and Unraveling the Resulting Data to Drive Clinical Trial Success


Biomarkers can deliver powerful advantages to clinical trials—if they are used correctly. Chad Clark, President, Precision for Medicine; Scott Marshall, Managing Director, Translational Informatics and Diagnostic Services, Precision for Medicine; and Cliff Culver, Senior Vice President, Precision Medicine Group, share their insights in this article for the Journal of Clinical Trials.

Access the full article below.


Journal of Clinical Trials – Using selection biomarkers and unravelling
This article originally appeared in Volume 11, Issue 1 of the Journal for ClinicalStudies.


Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.